Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Simvastatin is effective in killing the radioresistant breast carcinoma cells
Avtorji:ID Aschenbrenner, Bertram (Avtor)
ID Negro, Giulia (Avtor)
ID Savic, Dragana (Avtor)
ID Sorokin, Maxim (Avtor)
ID Buzdin, Anton A. (Avtor)
ID Ganswindt, Ute Maria (Avtor)
ID Čemažar, Maja (Avtor)
ID Serša, Gregor (Avtor)
ID Skvortsov, Sergej (Avtor)
ID Skvortsova, Ira (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://sciendo.com/article/10.2478/raon-2021-0020
 
.pdf PDF - Predstavitvena datoteka, prenos (1,76 MB)
MD5: 6EA4208607993EC488B9FD489B0C765C
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. Statins, small molecular 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are widely used to lower cholesterol levels in lipid-metabolism disorders. Recent preclinical and clinical studies have shown that statins exert beneficial effects in the management of breast cancer by increasing recurrence free survival. Unfortunately, the underlying mechanisms remain elusive. Materials and methods. Simvastatin, one of the most widely prescribed lipophilic statins was utilized to investigate potential radiosensitizing effects and an impact on cell survival and migration in radioresistant breast cancer cell lines. Results. Compared to parental cell counterparts, radioresistant MDA-MB-231-RR, T47D-RR andAu565-RR cells were characterized by upregulation of 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMGCR) expression accom-panied by epithelial-to-mesenchymal transition (EMT) activation. Radioresistant breast cancer cells can be killed by simvastatin via mobilizing of a variety of pathways involved in apoptosis and autophagy. In the presence of simvasta-tin migratory abilities and vimentin expression is diminished while E-cadherin expression is increased. Conclusions. The present study suggests that simvastatin may effectively eradicate radioresistant breast carcinoma cells and diminish their mesenchymal phenotypes.
Ključne besede:radiotherapy, breast cancer, radioresistant cells
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.09.2021
Založnik:Association of Radiology and Oncology
Leto izida:2021
Št. strani:str. 305-316, VI
Številčenje:Vol. 55, no. 3
Izvor:Ljubljana
PID:20.500.12556/DiRROS-19620 Novo okno
UDK:602
ISSN pri članku:1318-2099
DOI:10.2478/raon-2021-0020 Novo okno
COBISS.SI-ID:78947843 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:22.07.2024
Število ogledov:4
Število prenosov:6
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:radioterapija, rak dojke, radiorezistentne celice


Nazaj